Compare PASW & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PASW | HIND |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | Hong Kong | United States |
| Employees | N/A | 2 |
| Industry | Apparel | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0M | 15.2M |
| IPO Year | 2021 | 2016 |
| Metric | PASW | HIND |
|---|---|---|
| Price | $1.55 | $1.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.83 |
| AVG Volume (30 Days) | ★ 480.5K | 11.4K |
| Earning Date | 08-07-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 64.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $319,714.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $82.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.43 |
| 52 Week Low | $0.08 | $1.53 |
| 52 Week High | $6.25 | $5.88 |
| Indicator | PASW | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 33.05 |
| Support Level | $0.13 | N/A |
| Resistance Level | $6.25 | $2.29 |
| Average True Range (ATR) | 0.92 | 0.12 |
| MACD | -0.35 | -0.01 |
| Stochastic Oscillator | 9.65 | 8.80 |
Ping An Biomedical Co Ltd formerly Majestic Ideal Holdings Ltd is a Cayman Islands-based holding company, conducting operations through its PRC subsidiary, NewBrand. The group is a provider of SCM services in the apparel industry, offering solutions for a broad range of yarn products, textiles, and finished garments. Its service offerings encompass every key aspect of the supply chain of textile products, such as market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management. The group has two reportable segments, yarns and finished garments. The majority of its revenue is generated from the sale of yarns, including pure cashmere and cashmere-mix yarn, merino wool, cotton, and fancy yarn.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.